Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 6874Lung Neoplasms 5105Small Cell Lung Carcinoma 1166Breast Neoplasms 855Neoplasms 762Colorectal Neoplasms 670Melanoma 566Ovarian Neoplasms 506Neoplasm Metastasis 481Pancreatic Neoplasms 473Adenocarcinoma of Lung 398Stomach Neoplasms 396Prostatic Neoplasms 370Head and Neck Neoplasms 368Carcinoma, Renal Cell 350Esophageal Neoplasms 337Squamous Cell Carcinoma of Head and Neck 325Mesothelioma, Malignant 324Colonic Neoplasms 294Mesothelioma 289Urinary Bladder Neoplasms 262Brain Neoplasms 254Uterine Cervical Neoplasms 243Triple Negative Breast Neoplasms 223Sarcoma 198Endometrial Neoplasms 196Carcinoma, Hepatocellular 186NSCLC 167Pleural Effusion, Malignant 160Kidney Neoplasms 160

Interventions

N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
EGFR Mutated EGFR TKI Naive Metastatic NSCLC × Thoracic × Clear all
NCT02206763 2019-02-01

Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Sierra Oncology LLC - a GSK company

Phase 1 Terminated
11 enrolled
Thoracic

EGFR Mutated EGFR TKI Naive Metastatic NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡